Pub. Date : 2015 Jun
PMID : 25818403
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. | veliparib | BRCA2 DNA repair associated | Homo sapiens |
2 | BACKGROUND: Veliparib is a potent small molecule inhibitor of PARP-1/2, which is cytotoxic in tumor cells with deficiencies in BRCA1 or BRCA2. | veliparib | BRCA2 DNA repair associated | Homo sapiens |